Malignant Mesothelioma — Trials

Malignant Mesothelioma — Trials · CancerIndex

Clinical trials

Registered studies

478 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 96
Recruiting: 55
Ph III recruiting: 1
Growth YoY: —
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.4%
Trials / 1,000 deaths: 45.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (81)

clinicaltrialsPublishedShowing 51–100 of 109 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03048474	Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma(INITIATE)	completed	Phase 2	36	The Netherlands Cancer InstituteOTHER	1	Jan 20, 2021	clinicaltrials
NCT02610140	Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)	completed	Phase 2	248	BayerINDUSTRY	14	Nov 4, 2020	clinicaltrials